This is an unofficial translation of a notice to the Annual General Meeting in ODI Pharma AB (publ), originally drafted in Swedish. In case of
any discrepancies between the Swedish original and this translation, the Swedish version shall prevail.
Today, the 13th of December 2021, ODI Pharma AB (publ) held its Annual General Meeting (“AGM”). A summary of the resolutions follows below. The resolutions were made with the required majority.
Adoption of the income statement and balance sheet
The AGM adopted the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet.
Discharge of liability for board members and the CEO
The AGM resolved to grant each member of the Board of Directors and the CEO discharge of liability.
Allocation of the company’s profit or loss
The AGM resolved to dispose the company's results according to the Board of Directors’ proposal in the annual report. The AGM also resolved that no dividend shall be paid for the financial year 2020/2021.
Resolution on the fees to be paid to the members of the Board of Directors and the auditor
The AGM resolved that remuneration for the Board of Directors should amount to 100,000 SEK for the Chairman of the board Volker Wiederrich, and 100,000 SEK each for the board members Derek Simmross and Karina Kilinski. In addition, the AGM decided that remuneration should amount to 75,500 SEK for the board member Gösta Lidén.
Furthermore, the AGM resolved that an auditor’s fees should be paid according to approved invoice in accordance with customary charging standards.
Election of the board of directors and accounting firm or auditor
The AGM decided to re-elect Derek Simmross, Karina Kilinski and Gösta Lidén as ordinary board members. It was also decided to re-elect Volker Wiederrich as an ordinary board member and as Chairman of the Board. Furthermore, the AGM resolved to re-elect the company's audit firm Örhlings PriceWaterhouseCoopers AB until the end of the Annual General Meeting that will be held next financial year.
For more information on ODI Pharma, please contact:
Derek Simmross, CEO, ODI Pharma AB
ODI Pharma AB
ODI Pharma, based on its European network, subsidiaries, and partners, is a producer and representative of finished pharmaceutical cannabis and cosmetics products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be at the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renowned partners in the industry to achieve its goals.